Terpene Blend Compositions for Indication-Specific Cannabinoid Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for compositions comprising different combinations of terpenes and cannabinoids for the treatment of specific indications, such as sleep disorders, neuroprotection, pain, and neurodegenerative conditions, as existing products do not effectively address these issues.
Innovation Solution
Compositions comprising specific mixtures of terpenes, including myrcene, terpineol, caryophyllene, and nerolidol, combined with an oil carrier, are administered to subjects to treat conditions like insomnia, neuroprotection, pain, and other symptoms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing terpene-cannabinoid products are used, then general cannabinoid effects are provided, but specific therapeutic outcomes for sleep disorders, neuroprotection, and pain are not achieved
Solution Approach 1:
The patent segments the broad category of terpene-cannabinoid products into distinct compositions tailored for specific indications. Each composition contains a unique Terpene Blend (TB-1 through TB-5) with specific terpene ratios optimized for particular therapeutic goals such as sleep disorders, neuroprotection, pain management, anxiety/depression, and seizure disorders. This segmentation allows each product to reliably address its specific indication rather than providing generic cannabinoid effects.
Solution Approach 2:
The patent applies local quality by assigning different terpene compositions to different therapeutic indications. Each Terpene Blend has a specific quality profile matched to its intended use: TB-1 with myrcene and linalool for sleep promotion, TB-2 with alpha-pinene and limonene for neuroprotection, TB-3 with beta-caryophyllene for pain relief, TB-4 with specific ratios for anxiety and depression, and TB-5 for seizure disorders. This ensures each composition has the local quality needed for its specific therapeutic purpose.
2Reliability
If single-terpene or simple terpene mixtures are used, then composition simplicity is maintained, but therapeutic efficacy for specific conditions is insufficient
Solution Approach 1:
The patent employs composite materials by creating complex Terpene Blends that combine multiple terpenes in specific ratios. Each blend contains 3-5 different terpenes (e.g., TB-1 contains myrcene, linalool, and other terpenes in defined proportions) that work synergistically to enhance cannabinoid effects and provide specific therapeutic outcomes. These composite terpene compositions deliver superior therapeutic efficacy compared to single-terpene products while maintaining standardized formulations for reliability.
Solution Approach 2:
The patent applies parameter changes by precisely controlling the concentration and ratio of individual terpenes within each blend. For example, TB-1 specifies myrcene at 1000-4500 ppm and linalool at 500-4500 ppm, while TB-2 specifies alpha-pinene at 1000-4500 ppm and limonene at 1000-4000 ppm. These parameter specifications optimize therapeutic efficacy for each indication while maintaining manageable composition complexity through standardized ranges.
3Reliability
If terpene compositions are optimized for specific indications, then therapeutic outcomes are improved, but product versatility across multiple conditions is reduced
Solution Approach 1:
Rather than attempting to create a single versatile product, the patent segments the market into distinct indications, each served by a specialized Terpene Blend. This allows each composition to be optimized for its specific purpose (sleep, neuroprotection, pain, etc.) while the overall product line maintains versatility through offering multiple specialized options. Each blend's specificity translates to reliable therapeutic outcomes for its target indication.
Solution Approach 2:
The patent achieves universality at the system level rather than the individual product level. The full range of Terpene Blends (TB-1 through TB-5) collectively covers multiple indications, providing multi-functionality across the product line. Each individual blend specializes in one or more related conditions, and the combination of blends offers comprehensive coverage for various neurological and psychiatric disorders, maintaining overall versatility while ensuring indication-specific optimization.
Data Source
AI summary
Provided are compositions comprising terpene mixtures consisting of 1000-4500 ppm myrcene, 1000-4000 ppm terpineol, 1000-5500 ppm caryophyllene and 1000-45000 ppm nerolidol; 1000-4500 ppm alpha-pinene, 1000-4000 ppm sabinene, 1000-4000 ppm limonene, 500-4000 ppm borneol and 1000-4500 ppm caryophyllene; 1000-4500 ppm alpha-pinene, 1000-4000 ppm linalool, 1000-4000 ppm terpineol, 1000-4000 ppm borneol, 1000-4500 ppm caryophyllene and 1000-4000 ppm nerolidol; 1000-4000 ppm myrcene, 500-5000 ppm linalool, 1000-4500 ppm caryophyllene and 500-4500 ppm nerolidol; or 1000-5500 ppm alpha-pinene, 1000-4000 ppm limonene, 500-4000 ppm linalool and 1000-4500 ppm caryophyllene, and uses in therapy.